Core Indicators for Monitoring EHE: National HIV Surveillance (NHSS) Data reported to CDC through September 2020; PrEP data reported through June 2020

HIV Surveillance Data Tables

Core Indicators for Monitoring the Ending the HIV Epidemic Initiative (Preliminary Data) : HIV Diagnoses and Linkage to HIV Medical Care, 2019 and 2020 (Reported through September 2020); and Preexposure Prophylaxis (PrEP), 2018 (Updated), 2019 and 2020 (Reported through June 2020)

This issue of HIV Surveillance Data Tables is published by the Division of HIV/AIDS Prevention (DHAP), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through September 2020.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested Citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): HIV diagnoses and linkage to HIV medical care, 2019 and 2020 (reported through September 2020); and preexposure prophylaxis (PrEP), 2018 (updated), 2019 and 2020 (reported through June 2020). HIV Surveillance Data Tables 2021;2(No. 1). http://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-1-no-7/index.html. Published February 2021. Accessed [date]

Report volume and number updated February 2021.

Download the full report pdf icon[PDF – 913 KB].

The Ending the HIV Epidemic: A Plan for America (EHE) initiative will leverage critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% in 5 years and by at least 90% in 10 years. Throughout the initiative, the Centers for Disease Control and Prevention (CDC) will routinely release HIV Surveillance Data Tables on the 6 core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the Core Indicators for Monitoring the Ending the HIV Epidemic Initiative report at https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-1-no-1/index.html.

The tables included in this report provide preliminary data on HIV diagnoses and linkage to HIV medical care reported to CDC as of September 2020 for the years 2019 and 2020, and data on preexposure prophylaxis (PrEP) coverage for the year 2018 (updated), 2019 and 2020 (preliminary). Data for the 3 indicators are provided at the national-, state-, and county-levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated. Data reported to the National HIV Surveillance System (NHSS) are considered preliminary until a 12-month reporting lag has been reached. Because the data in this report are provided by using an NHSS dataset produced prior to reaching a 12-month reporting lag, the data should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions [2].

Tabulation and Presentation of Data

Diagnosis of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥13 years whose HIV infection was diagnosed during January 2019 through September 2020 (Tables 1a–d).

Data presented were reported (after the removal of personally identifiable information) to CDC’s NHSS through September 2020. Please use caution when inter­preting data on diagnoses of HIV infection. HIV surveil­lance reports may not be representative of all per­sons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential, name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not repre­sent all persons who tested positive for HIV infection.

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution.  In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state and local jurisdictions.

More information on counting diagnoses of HIV infection can be found at https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-31/index.html (HIV Surveillance Report, 2018 [Updated]).

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥13 years whose HIV infection was diagnosed during January 2019 through June 2020, and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥13 years whose HIV infection was diagnosed during the specified period and who had ≥1 CD4 or viral load (VL) test within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥13 years whose HIV infection was diagnosed during the specified period. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data for the year 2020 on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January through June of 2020 and that were reported to NHSS through September 2020. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution.  In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state and local jurisdictions.

More information on calculating linkage to care can be found at Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018 pdf icon[PDF – 4 MB].

Preexposure Prophylaxis (PrEP) Coverage

PrEP coverage, reported as a percentage, is defined as the number of persons aged ≥16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥16 years who had indications for PrEP during the specified year (Tables 3a–c).

Number of persons prescribed, which is reported as a case count, is defined as the number of persons aged ≥16 years classified as having been prescribed PrEP during the specified year.

PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage. Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons Prescribed PrEP

National pharmacy data from the IQVIA Real World Data-Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 92% of all prescriptions from retail pharmacies and 60%–86% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) were prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [3–5]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the FDA in October 2019. Starting 2019, TAF/FTC was included in the algorithm to estimate number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database and race/ethnicity data are available for <40% of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA data include white, black/African American, Hispanic/Latino, and Asian/other. The number of persons prescribed PrEP for each racial/ethnic group presented was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity was unknown.

Geographic Designations

In the IQVIA database, a person’s location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties using data from (a) the U.S Census Bureau’s American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [6], and (b) the U.S Department of Housing and Urban Development’s ZIP Code Crosswalk Files [7]. Because of reliability concerns, subnational estimates of <40 are not included.

Persons with PrEP Indications

U.S. Census Bureau datasets were used to estimate the number of men who have sex with men (MSM) in a jurisdiction. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [8]. For the 2018 denominator,  this proportion was updated with recent NHANES data.

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of HIV diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [8]. Jurisdictional estimates were rounded to the nearest 10. Beginning in 2018, methods were adjusted to provide the estimated number of Asians and persons of other race ethnicities in addition to Black/African Americans, Hispanic/Latino, and white persons.

The tables included in this report provide updated data on PrEP coverage for the year 2018, and preliminary data for the years 2019 and 2020 (from January through June) using the IQVIA data reported through June 2020. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator lags the availability of a numerator by approximately 1 year. For this release of the HIV Surveillance Data Tables, 2018 denominators were used for 2018, 2019 and 2020 PrEP coverage data.

References

HHS. What is ‘Ending the HIV Epidemic: A Plan for America’? https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. Published October 4, 2019. Accessed July 13, 2020.

  1. HHS. What is ‘Ending the HIV Epidemic: A Plan for America’? https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overviewexternal icon. Published October 4, 2019. Accessed July 13, 2020.
  2. CDC [Schuchat A, CDC COVID-19 Response Team]. Public Health Response to the Initiation and Spread of Pandemic COVID-19 in the United States, February 24–April 21, 2020. MMWR 2020;69(18):551–556. doi:http://dx.doi.org/10.15585/mmwr.mm6918e2external icon
  3. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV pre-exposure prophylaxis among commercially insured persons—United States, 2010–2014. Clin Infect Dis 2017;64(2):144–149. doi:10.1093/cid/ciw701.
  4. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV pre-exposure prophylaxis, by race and ethnicity—United States, 2014–2016. MMWR 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3.
  5. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. Public Health Rep 2020;135(2):202–210. doi:10.1177/0033354920904085
  6. U.S. Census Bureau. American Community Survey 5-year data (2009-2018). https://www.census.gov/data/developers/data-sets/acs-5year.2018.htmlexternal icon. Published December 19, 2019. Accessed July 13, 2020.
  7. HUD. HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.htmlexternal icon. Published 2019. Accessed July 13, 2020.
  8. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for pre-exposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4.

Suggested Citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): HIV diagnoses and linkage to HIV medical care, 2019 and 2020 (reported through September 2020); and preexposure prophylaxis (PrEP), 2018 (updated), 2019 and 2020 (reported through June 2020). HIV Surveillance Data Tables 2021;2(No. 1). http://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-1-no-7/index.html. Published February 2021. Accessed [date]

Acknowledgments

Publication of HIV Surveillance Data Tables was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Dawn Smith, Xiaohong Hu, Jianmin Li, Baohua Wu, Chan Jin, Shihua Wang, Weiming Zhu, Anne Patala, Lei Yu, Norma Harris, and Michael Friend and the Web and Consumer Services Team of the Prevention Communications Branch (editing and desktop publishing).

Table 1a. Diagnoses of HIV infection among persons aged ≥13 years, by selected characteristics, January 2019 through September 2020—United States (preliminary)
2019 2020 (January – September)
Total No. Total No.
Gender
Male 28,469 13,635
Female 6,784 3,191
Transgender male-to-femalea 610 273
Transgender female-to-malea 42 17
Additional gender identityb 19 6
Age at diagnosis (yr)
13–24 7,483 3,419
25–34 12,902 6,238
35–44 6,993 3,269
45–54 4,811 2,321
≥55 3,735 1,875
Race/ethnicity
American Indian/Alaska Native 206 105
Asian 731 364
Black/African American 15,409 7,672
Hispanic/Latinoc 9,574 4,131
Native Hawaiian/other Pacific Islander 65 37
White 9,055 4,525
Multiple races 884 288
Transmission categoryd
Male-to-male sexual contact 23,724 11,552
Injection drug use
      Male 1,353 674
      Female 1,094 477
Male-to-male sexual contact and injection drug use 1,426 553
Heterosexual contacte
      Male 2,558 1,115
      Female 5,708 2,714
Otherf
      Male 34 19
      Female 28 18
Region of residenceg
Northeast 5,242 2,326
Midwest 4,725 2,255
South 18,868 9,419
West 7,089 3,122
Total 35,924 17,122

Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

aTransgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
cHispanics/Latinos can be of any race.
dData have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.
eHeterosexual contact with a person known to have, or to be at high risk for, HIV infection.
fIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
gData are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection among persons aged ≥13 years, by selected characteristics, January 2019 through September 2020—United States and 6 dependent areas (preliminary)
2019 2020 (January – June)
Total No. Total No.
Gender
Male 28,789 13,766
Female 6,864 3,217
Transgender male-to-femalea 612 274
Transgender female-to-malea 42 17
Additional gender identityb 19 6
Age at diagnosis (yr)
13–24 7,543 3,451
25–34 13,014 6,277
35–44 7,071 3,304
45–54 4,877 2,346
≥55 3,821 1,902
Race/ethnicity
American Indian/Alaska Native 206 105
Asian 737 364
Black/African American 15,414 7,674
Hispanic/Latinoc 9,954 4,283
Native Hawaiian/other Pacific Islander 69 37
White 9,062 4,529
Multiple races 884 288
Transmission categoryd
Male-to-male sexual contact 23,944 11,649
Injection drug use
      Male 1,376 687
      Female 1,099 478
Male-to-male sexual contact and injection drug use 1,438 558
Heterosexual contacte
      Male 2,624 1,132
      Female 5,783 2,738
Otherf
      Male 34 19
      Female 28 18
Region of residenceg
Northeast 5,242 2,326
Midwest 4,725 2,255
South 18,868 9,419
West 7,089 3,122
U.S. dependent areas 402 158
Total 36,326 17,280

Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

aTransgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
cHispanics/Latinos can be of any race.
dData have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.
eHeterosexual contact with a person known to have, or to be at high risk for, HIV infection.
fIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
gData are based on residence at time of diagnosis of HIV infection.

Table 1c. Diagnoses of HIV infection among persons aged ≥13 years, by area of residence, January 2019 through September 2020—United States and 6 dependent areas (preliminary)
2019 2020 (January – September)
Area of residence Total No. Total No.
Alabama 640 346
Alaska 27 22
Arizona 765 421
Arkansas 285 193
California 4,230 1,746
Colorado 460 211
Connecticut 207 83
Delaware 93 70
District of Columbia 247 112
Florida 4,402 2,535
Georgia 2,315 1,058
Hawaii 65 23
Idaho 27 2
Illinois 1,238 441
Indiana 485 257
Iowa 100 65
Kansas 132 74
Kentucky 314 150
Louisiana 887 499
Maine 30 12
Maryland 926 441
Massachusetts 536 216
Michigan 675 370
Minnesota 274 146
Mississippi 477 270
Missouri 489 245
Montana 26 3
Nebraska 81 34
Nevada 510 156
New Hampshire 30 15
New Jersey 1,035 388
New Mexico 147 42
New York 2,332 1,127
North Carolina 1,370 748
North Dakota 36 11
Ohio 975 479
Oklahoma 309 121
Oregon 198 115
Pennsylvania 989 456
Rhode Island 72 22
South Carolina 688 466
South Dakota 33 12
Tennessee 768 428
Texas 4,176 1,452
Utah 136 96
Vermont 11 7
Virginia 827 440
Washington 485 278
West Virginia 144 90
Wisconsin 207 121
Wyoming 13 7
Subtotal 35,924 17,122
U.S. dependent areas
American Samoa 0 0
Guam 10 0
Northern Mariana Islands 2 0
Puerto Rico 383 156
Republic of Palau 0 0
U.S. Virgin Islands 7 2
Subtotal 402 158
Total 36,326 17,280

Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 1d. Diagnoses of HIV infection among persons aged ≥13 years, by area of residence, January 2019 through September 2020—Ending the HIV Epidemic Phase I jurisdictions (preliminary)
2019 2020 (January – September)
Area of residence Total No. Total No.
Arizona
  Maricopa County 517 304
California
  Alameda County 220 105
  Los Angeles County 1,447 618
  Orange County 246 178
  Riverside County 262 127
  Sacramento County 86 6
  San Bernardino County 271 51
  San Diego County 360 76
  San Francisco County 207 103
District of Columbia 247 112
Florida
  Broward County 597 349
  Duval County 272 164
  Hillsborough County 268 197
  Miami-Dade County 1,154 598
  Orange County 470 273
  Palm Beach County 237 152
  Pinellas County 185 115
Georgia
  Cobb County 165 63
  DeKalb County 330 136
  Fulton County 552 308
  Gwinnett County 195 71
Illinois
  Cook County 873 343
Indiana
  Marion County 204 103
Louisiana
  East Baton Rouge Parish 152 86
  Orleans Parish 159 71
Maryland
  Baltimore City 201 99
  Montgomery County 134 56
  Prince George’s County 279 128
Massachusetts
  Suffolk County 135 67
Michigan
  Wayne County 284 159
Nevada
  Clark County 448 126
New Jersey
  Essex County 227 101
  Hudson County 147 62
New York
  Bronx County 500 181
  Kings County 470 264
  New York County 342 170
  Queens County 351 186
North Carolina
  Mecklenburg County 267 138
Ohio
  Cuyahoga County 159 98
  Franklin County 217 123
  Hamilton County 171 65
Pennsylvania
  Philadelphia County 441 186
Puerto Rico
  San Juan Municipio 87 41
Tennessee
  Shelby County 260 159
Texas
  Bexar County 350 183
  Dallas County 739 407
  Harris County 1,155 225
  Tarrant County 305 126
  Travis County 178 79
Washington
  King County 248 139

Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 2a. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020 among persons aged ≥13 years, by selected characteristics—41 states and the District of Columbia (preliminary)
2019
Total diagnoses ≥1 CD4 or VL tests No CD4 or VL test
No. No. % No. %
Gender
Male 25,539 20,836 81.6 4,703 18.4
Female 6,018 4,828 80.2 1,190 19.8
Transgender male-to-femalea 548 450 82.1 98 17.9
Transgender female-to-malea 37 33 89.2 4 10.8
Additional gender identityb 17 15 88.2 2 11.8
Age at diagnosis (yr)
13–24 6,702 5,307 79.2 1,395 20.8
25–34 11,570 9,343 80.8 2,227 19.2
35–44 6,267 5,167 82.4 1,100 17.6
45–54 4,295 3,570 83.1 725 16.9
≥55 3,325 2,775 83.5 550 16.5
Race/ethnicity
American Indian/Alaska Native 163 134 82.2 29 17.8
Asian 663 550 83.0 113 17.0
Black/African American 14,023 11,052 78.8 2,971 21.2
Hispanic/Latinoc 8,563 7,202 84.1 1,361 15.9
Native Hawaiian/other Pacific Islander 62 51 82.3 11 17.7
White 7,878 6,509 82.6 1,369 17.4
Multiple races 807 664 82.3 143 17.7
Transmission categoryd
Male-to-male sexual contact 21,431 17,601 82.1 3,830 17.9
Injection drug use
      Male 1,105 843 76.3 262 23.7
      Female 943 713 75.6 230 24.4
Male-to-male sexual contact and injection drug use 1,257 1,006 80.0 251 20.0
Heterosexual contacte
      Male 2,277 1,823 80.1 454 19.9
      Female 5,092 4,131 81.1 961 18.9
Totalf 32,159 26,162 81.4 5,997 18.6
Table 2a. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020 among persons aged ≥13 years, by selected characteristics—41 states and the District of Columbia (preliminary)
2020 (January – June)
Total diagnoses ≥1 CD4 or VL tests No CD4 or VL test
No. No. % No. %
Gender
Male 9,283 7,603 81.9 1,680 18.1
Female 2,198 1,796 81.7 402 18.3
Transgender male-to-femalea 198 169 85.4 29 14.6
Transgender female-to-malea 7 7 100.0 0 0.0
Additional gender identityb 4 4 100.0 0 0.0
Age at diagnosis (yr)
13–24 2,343 1,849 78.9 494 21.1
25–34 4,265 3,494 81.9 771 18.1
35–44 2,279 1,875 82.3 404 17.7
45–54 1,566 1,313 83.8 253 16.2
≥55 1,237 1,048 84.7 189 15.3
Race/ethnicity
American Indian/Alaska Native 53 44 83.0 9 17.0
Asian 251 218 86.9 33 13.1
Black/African American 5,310 4,257 80.2 1,053 19.8
Hispanic/Latinoc 2,880 2,404 83.5 476 16.5
Native Hawaiian/other Pacific Islander 24 20 83.3 4 16.7
White 2,954 2,453 83.0 501 17.0
Multiple races 218 183 83.9 35 16.1
Transmission categoryd
Male-to-male sexual contact 7,868 6,461 82.1 1,407 17.9
Injection drug use
      Male 448 358 79.8 90 20.2
      Female 334 270 80.8 64 19.2
Male-to-male sexual contact and injection drug use 374 306 81.9 68 18.1
Heterosexual contacte
      Male 783 640 81.8 142 18.2
      Female 1,858 1,522 81.9 337 18.1
Totalf 11,690 9,579 81.9 2,111 18.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL). CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through June of 2020, that were reported to CDC through June 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.

aTransgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
cHispanics/Latinos can be of any race.
dData have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and include transgender persons.
eHeterosexual contact with a person known to have, or to be at high risk for, HIV infection.
fIncludes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020, among persons aged ≥13 years, by area of residence—41 states and the District of Columbia (preliminary)
2019
Total diagnoses ≥1 CD4 or VL tests No CD4 or VL test
No. No. % No. %
Alabama 640 507 79.2 133 20.8
Alaska 27 23 85.2 4 14.8
California 4,230 3,493 82.6 737 17.4
Colorado 460 383 83.3 77 16.7
Delaware 93 71 76.3 22 23.7
District of Columbia 247 219 88.7 28 11.3
Florida 4,402 3,680 83.6 722 16.4
Georgia 2,315 1,896 81.9 419 18.1
Hawaii 65 55 84.6 10 15.4
Illinois 1,238 1,027 83.0 211 17.0
Indiana 485 303 62.5 182 37.5
Iowa 100 91 91.0 9 9.0
Louisiana 887 730 82.3 157 17.7
Maine 30 28 93.3 2 6.7
Maryland 926 808 87.3 118 12.7
Massachusetts 536 484 90.3 52 9.7
Michigan 675 568 84.1 107 15.9
Minnesota 274 252 92.0 22 8.0
Mississippi 477 338 70.9 139 29.1
Missouri 489 376 76.9 113 23.1
Montana 26 22 84.6 4 15.4
Nebraska 81 65 80.2 16 19.8
Nevada 510 426 83.5 84 16.5
New Hampshire 30 27 90.0 3 10.0
New Mexico 147 130 88.4 17 11.6
New York 2,332 2,032 87.1 300 12.9
North Carolina 1,370 1,082 79.0 288 21.0
North Dakota 36 33 91.7 3 8.3
Ohio 975 816 83.7 159 16.3
Oklahoma 309 214 69.3 95 30.7
Oregon 198 173 87.4 25 12.6
Rhode Island 72 63 87.5 9 12.5
South Carolina 688 601 87.4 87 12.6
South Dakota 33 26 78.8 7 21.2
Tennessee 768 524 68.2 244 31.8
Texas 4,176 3,102 74.3 1,074 25.7
Utah 136 105 77.2 31 22.8
Virginia 827 650 78.6 177 21.4
Washington 485 433 89.3 52 10.7
West Virginia 144 106 73.6 38 26.4
Wisconsin 207 187 90.3 20 9.7
Wyoming 13 13 100 0 0.0
Total 32,159 26,162 81.4 5,997 18.6
Table 2b. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020, among persons aged ≥13 years, by area of residence—41 states and the District of Columbia (preliminary)
2020 (January – June)
Total diagnoses ≥1 CD4 or VL tests No CD4 or VL test
No. No. % No. %
Alabama 289 232 80.3 57 19.7
Alaska 16 16 100.0 0 0.0
California 1,420 1,221 86.0 199 14.0
Colorado 135 119 88.1 16 11.9
Delaware 55 39 70.9 16 29.1
District of Columbia 88 80 90.9 8 9.1
Florida 1,802 1,520 84.4 282 15.6
Georgia 796 683 85.8 113 14.2
Hawaii 19 17 89.5 2 10.5
Illinois 374 326 87.2 48 12.8
Indiana 217 164 75.6 53 24.4
Iowa 44 40 90.9 4 9.1
Louisiana 331 247 74.6 84 25.4
Maine 10 9 90.0 1 10.0
Maryland 347 322 92.8 25 7.2
Massachusetts 185 157 84.9 28 15.1
Michigan 241 199 82.6 42 17.4
Minnesota 108 93 86.1 15 13.9
Mississippi 198 148 74.7 50 25.3
Missouri 174 135 77.6 39 22.4
Montana 3 2 66.7 1 33.3
Nebraska 32 27 84.4 5 15.6
Nevada 151 121 80.1 30 19.9
New Hampshire 12 11 91.7 1 8.3
New Mexico 32 28 87.5 4 12.5
New York 894 784 87.7 110 12.3
North Carolina 532 441 82.9 91 17.1
North Dakota 11 10 90.9 1 9.1
Ohio 410 366 89.3 44 10.7
Oklahoma 89 55 61.8 34 38.2
Oregon 77 68 88.3 9 11.7
Rhode Island 20 11 55.0 9 45.0
South Carolina 313 281 89.8 32 10.2
South Dakota 12 11 91.7 1 8.3
Tennessee 323 229 70.9 94 29.1
Texas 1,206 769 63.8 437 36.2
Utah 57 27 47.4 30 52.6
Virginia 306 248 81.0 58 19.0
Washington 206 189 91.7 17 8.3
West Virginia 60 47 78.3 13 21.7
Wisconsin 90 83 92.2 7 7.8
Wyoming 5 4 80 1 20.0
Total 11,690 9,579 81.9 2,111 18.1

Abbreviations: CD4, CD4+ T -lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL). CDC, the Centers for Disease Control and Prevention [footnotes only].
“Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.”

Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through June of 2020, that were reported to CDC through September 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.

Table 2c. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020, among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)
2019
Total diagnoses ≥1 CD4 or VL tests No CD4 or VL test
No. No. % No. %
California
  Alameda County 220 196 89.1 24 10.9
  Los Angeles County 1,447 1,160 80.2 287 19.8
  Orange County 246 199 80.9 47 19.1
  Riverside County 262 211 80.5 51 19.5
  Sacramento County 86 77 89.5 9 10.5
  San Bernardino County 271 199 73.4 72 26.6
  San Diego County 360 311 86.4 49 13.6
  San Francisco County 207 199 96.1 8 3.9
District of Columbia 247 219 88.7 28 11.3
Florida
  Broward County 597 522 87.4 75 12.6
  Duval County 272 209 76.8 63 23.2
  Hillsborough County 268 230 85.8 38 14.2
  Miami-Dade County 1,154 972 84.2 182 15.8
  Orange County 470 370 78.7 100 21.3
  Palm Beach County 237 187 78.9 50 21.1
  Pinellas County 185 158 85.4 27 14.6
Georgia
  Cobb County 165 144 87.3 21 12.7
  DeKalb County 330 271 82.1 59 17.9
  Fulton County 552 464 84.1 88 15.9
  Gwinnett County 195 162 83.1 33 16.9
Illinois
  Cook County 873 722 82.7 151 17.3
Indiana
  Marion County 204 107 52.5 97 47.5
Louisiana
  East Baton Rouge Parish 152 134 88.2 18 11.8
  Orleans Parish 159 131 82.4 28 17.6
Maryland
  Baltimore City 201 172 85.6 29 14.4
  Montgomery County 134 121 90.3 13 9.7
  Prince George’s County 279 247 88.5 32 11.5
Massachusetts
  Suffolk County 135 124 91.9 11 8.1
Michigan
  Wayne County 284 243 85.6 41 14.4
Nevada
  Clark County 448 371 82.8 77 17.2
New York
  Bronx County 500 436 87.2 64 12.8
  Kings County 470 400 85.1 70 14.9
  New York County 342 303 88.6 39 11.4
  Queens County 351 301 85.8 50 14.2
North Carolina
  Mecklenburg County 267 209 78.3 58 21.7
Ohio
  Cuyahoga County 159 142 89.3 17 10.7
  Franklin County 217 197 90.8 20 9.2
  Hamilton County 171 145 84.8 26 15.2
Pennsylvania
  Philadelphia County 441 374 84.8 67 15.2
Tennessee
  Shelby County 260 159 61.2 101 38.8
Texas
  Bexar County 350 249 71.1 101 28.9
  Dallas County 739 561 75.9 178 24.1
  Harris County 1,155 850 73.6 305 26.4
  Tarrant County 305 226 74.1 79 25.9
  Travis County 178 153 86.0 25 14.0
Washington
  King County 248 224 90.3 24 9.7
Table 2c. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020, among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)
2020 (January – June)
Total diagnoses ≥1 CD4 or VL tests No CD4 or VL test
No. No. % No. %
California
  Alameda County 87 72 82.8 15 17.2
  Los Angeles County 506 438 86.6 68 13.4
  Orange County 130 114 87.7 16 12.3
  Riverside County 96 75 78.1 21 21.9
  Sacramento County 6 4 66.7 2 33.3
  San Bernardino County 48 39 81.3 9 18.8
  San Diego County 75 70 93.3 5 6.7
  San Francisco County 74 70 94.6 4 5.4
District of Columbia 88 80 90.9 8 9.1
Florida
  Broward County 249 214 85.9 35 14.1
  Duval County 109 90 82.6 19 17.4
  Hillsborough County 139 117 84.2 22 15.8
  Miami-Dade County 431 361 83.8 70 16.2
  Orange County 191 169 88.5 22 11.5
  Palm Beach County 117 94 80.3 23 19.7
  Pinellas County 82 73 89.0 9 11.0
Georgia
  Cobb County 44 37 84.1 7 15.9
  DeKalb County 91 81 89.0 10 11.0
  Fulton County 227 195 85.9 32 14.1
  Gwinnett County 57 45 78.9 12 21.1
Illinois
  Cook County 284 249 87.7 35 12.3
Indiana
  Marion County 87 67 77.0 20 23.0
Louisiana
  East Baton Rouge Parish 63 52 82.5 11 17.5
  Orleans Parish 42 32 76.2 10 23.8
Maryland
  Baltimore City 80 72 90.0 8 10.0
  Montgomery County 49 47 95.9 2 4.1
  Prince George’s County 98 91 92.9 7 7.1
Massachusetts
  Suffolk County 57 51 89.5 6 10.5
Michigan
  Wayne County 107 87 81.3 20 18.7
Nevada
  Clark County 125 98 78.4 27 21.6
New York
  Bronx County 144 125 86.8 19 13.2
  Kings County 212 179 84.4 33 15.6
  New York County 136 114 83.8 22 16.2
  Queens County 144 132 91.7 12 8.3
North Carolina
  Mecklenburg County 90 74 82.2 16 17.8
Ohio
  Cuyahoga County 82 77 93.9 5 6.1
  Franklin County 95 84 88.4 11 11.6
  Hamilton County 60 55 91.7 5 8.3
Pennsylvania
  Philadelphia County 135 114 84.4 21 15.6
Tennessee
  Shelby County 126 80 63.5 46 36.5
Texas
  Bexar County 140 75 53.6 65 46.4
  Dallas County 302 195 64.6 107 35.4
  Harris County 207 138 66.7 69 33.3
  Tarrant County 105 66 62.9 39 37.1
  Travis County 70 43 61.4 27 38.6
Washington
  King County 96 90 93.8 6 6.3

Abbreviations: CD4, CD4+ T -lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL). CDC, the Centers for Disease Control and Prevention [footnotes only].
“Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.”

Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through June of 2020, that were reported to CDC through September 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.

Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020, among persons aged ≥16 years, by selected characteristics—United States (updated data for 2018; preliminary data for 2019, 2020)
2018 2019 2020 (January – June)
Persons Prescribed PrEPa Persons with PrEP Indicationsb PrEP Coveragec Persons Prescribed PrEPa Persons with PrEP Indicationsb PrEP Coveragec Persons Prescribed PrEPa Persons with PrEP Indicationsb PrEP Coveragec
Area of residence No. No. % No. No. % No. No. %
Sex at birth
Male 204,863 989,200 20.7 256,873 989,200 26.0 213,871 989,200 21.6
Female 15,688 227,010 6.9 21,697 227,010 9.6 15,992 227,010 7.0
Age (yr)
16–24 29,413 246,290 11.9 38,033 246,290 15.4 23,998 246,290 9.7
25–34 90,975 434,680 20.9 114,188 434,680 26.3 90,230 434,680 20.8
35–44 50,892 238,470 21.3 64,308 238,470 27.0 57,427 238,470 24.1
45–54 31,602 173,420 18.2 37,529 173,420 21.6 33,282 173,420 19.2
≥55 17,780 123,350 14.4 24,660 123,350 20.0 25,006 123,350 20.3
Race/ethnicityd
Asian/other 9,510 131,180 7.2 11,698 131,180 8.9 9,399 131,180 7.2
Black/African American 28,732 468,540 6.1 37,703 468,540 8.0 30,378 468,540 6.5
Hispanic/Latino 33,450 312,820 10.7 42,999 312,820 13.7 35,264 312,820 11.3
White 148,971 300,650 49.5 186,318 300,650 62.0 154,901 300,650 51.5
Total 220,662 1,216,210 18.1 278,718 1,216,210 22.9 229,943 1,216,210 18.9

Abbreviations: PrEP, preexposure propphylaxis; n/a, not available.

aEstimated using data from IQVIA pharmacy database reported through June 2020 based on an algorithm that included FDA approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
bEstimated using 2018 data from National HIV Surveilance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2018, 2019 and 2020 PrEP coverage data.
cPrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
dRace/ethnicity data were only available for <40% of persons prescribed PrEP each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020, among persons aged ≥16 years, by area of residence—United States and Puerto Rico (updated data for 2018; preliminary data for 2019, 2020)
2018 2019 2020 (January – June)
Persons Prescribed PrEPa Persons with PrEP Indicationsb PrEP Coveragec Persons Prescribed PrEPa Persons with PrEP Indicationsb PrEP Coveragec Persons Prescribed PrEPa Persons with PrEP Indicationsb PrEP Coveragec
Area of residence No. No. % No. No. % No. No. %
Alabama 1,531 11,020 13.9 1,882 11,020 17.1 1,542 11,020 14.0
Alaska 196 1,780 11.0 235 1,780 13.2 194 1,780 10.9
Arizona 3,531 25,780 13.7 4,654 25,780 18.1 3,944 25,780 15.3
Arkansas 610 5,130 11.9 776 5,130 15.1 636 5,130 12.4
California 36,360 165,030 22.0 42,775 165,030 25.9 33,998 165,030 20.6
Colorado 3,416 25,120 13.6 4,331 25,120 17.2 3,518 25,120 14.0
Connecticut 2,315 9,560 24.2 2,768 9,560 29.0 1,959 9,560 20.5
Delaware 413 4,400 9.4 477 4,400 10.8 371 4,400 8.4
District of Columbia 5,045 12,950 39.0 5,941 12,950 45.9 4,929 12,950 38.1
Florida 14,621 125,330 11.7 22,062 125,330 17.6 23,393 125,330 18.7
Georgia 6,318 39,030 16.2 8,774 39,030 22.5 7,452 39,030 19.1
Hawaii 686 4,360 15.7 848 4,360 19.4 698 4,360 16.0
Idaho 368 4,790 7.7 478 4,790 10.0 476 4,790 9.9
Illinois 13,935 55,860 24.9 16,788 55,860 30.1 12,801 55,860 22.9
Indiana 2,184 22,170 9.9 3,044 22,170 13.7 2,373 22,170 10.7
Iowa 1,171 4,760 24.6 1,456 4,760 30.6 1,133 4,760 23.8
Kansas 740 5,060 14.6 929 5,060 18.4 699 5,060 13.8
Kentucky 1,213 12,990 9.3 1,642 12,990 12.6 1,251 12,990 9.6
Louisiana 3,490 15,920 21.9 4,137 15,920 26.0 2,861 15,920 18.0
Maine 481 3,950 12.2 648 3,950 16.4 488 3,950 12.4
Maryland 3,997 27,300 14.6 5,129 27,300 18.8 3,905 27,300 14.3
Massachusetts 8,029 24,900 32.2 10,060 24,900 40.4 8,171 24,900 32.8
Michigan 3,511 29,570 11.9 4,541 29,570 15.4 3,610 29,570 12.2
Minnesota 3,498 21,720 16.1 4,258 21,720 19.6 3,324 21,720 15.3
Mississippi 647 4,530 14.3 949 4,530 20.9 716 4,530 15.8
Missouri 2,779 18,370 15.1 3,565 18,370 19.4 2,884 18,370 15.7
Montana 183 2,290 8.0 269 2,290 11.7 228 2,290 10.0
Nebraska 474 2,180 21.7 630 2,180 28.9 539 2,180 24.7
Nevada 1,514 11,390 13.3 2,205 11,390 19.4 1,758 11,390 15.4
New Hampshire 506 3,020 16.8 639 3,020 21.2 491 3,020 16.3
New Jersey 4,667 25,280 18.5 5,865 25,280 23.2 4,578 25,280 18.1
New Mexico 805 6,800 11.8 1,089 6,800 16.0 903 6,800 13.3
New York 30,291 72,640 41.7 35,640 72,640 49.1 27,212 72,640 37.5
North Carolina 3,981 32,490 12.3 5,486 32,490 16.9 4,625 32,490 14.2
North Dakota 164 1,520 10.8 202 1,520 13.3 157 1,520 10.3
Ohio 4,793 40,320 11.9 6,259 40,320 15.5 5,182 40,320 12.9
Oklahoma 830 11,030 7.5 1,210 11,030 11.0 1,089 11,030 9.9
Oregon 2,730 19,750 13.8 3,361 19,750 17.0 2,728 19,750 13.8
Pennsylvania 8,652 36,490 23.7 10,399 36,490 28.5 8,361 36,490 22.9
Puerto Rico 236 9,700 2.4 336 9,700 3.5 278 9,700 2.9
Rhode Island 871 3,880 22.4 1,111 3,880 28.6 907 3,880 23.4
South Carolina 1,243 10,390 12.0 1,780 10,390 17.1 1,559 10,390 15.0
South Dakota 97 910 10.7 148 910 16.3 105 910 11.5
Tennessee 2,614 22,460 11.6 3,949 22,460 17.6 3,678 22,460 16.4
Texas 17,672 123,790 14.3 23,490 123,790 19.0 20,464 123,790 16.5
Utah 1,485 6,840 21.7 2,008 6,840 29.4 1,758 6,840 25.7
Vermont 285 1,060 26.9 343 1,060 32.4 241 1,060 22.7
Virginia 3,183 31,430 10.1 4,565 31,430 14.5 3,945 31,430 12.6
Washington 8,667 40,050 21.6 10,496 40,050 26.2 9,091 40,050 22.7
West Virginia 376 5,250 7.2 600 5,250 11.4 405 5,250 7.7
Wisconsin 1,979 12,980 15.2 2,647 12,980 20.4 2,018 12,980 15.5
Wyoming 75 890 8.4 93 890 10.4 67 890 7.5

Abbreviations: PrEP, preexposure propphylaxis; n/a, not available.

aEstimated using data from IQVIA pharmacy database reported through June 2020 based on an algorithm that included FDA approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
bEstimated using 2018 data from National HIV Surveilance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2018, 2019 and 2020 PrEP coverage data.
cPrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020, among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (updated data for 2018; preliminary data for 2019, 2020)
2018 2019 2020 (January – June)
Persons Prescribed PrEPa Persons with PrEP Indicationsb PrEP Coveragec Persons Prescribed PrEPa Persons with PrEP Indicationsb PrEP Coveragec Persons Prescribed PrEPa Persons with PrEP Indicationsb PrEP Coveragec
Area of residence No. No. % No. No. % No. No. %
Arizona
Maricopa County 2,835 22,720 12.5 3,591 22,720 15.8 3,063 22,720 13.5
California
Alameda County 1,877 8,930 21.0 2,217 8,930 24.8 1,653 8,930 18.5
Los Angeles County 12,287 67,450 18.2 14,196 67,450 21.0 11,747 67,450 17.4
Orange County 1,628 10,510 15.5 2,114 10,510 20.1 1,737 10,510 16.5
Riverside County 1,356 11,080 12.2 1,754 11,080 15.8 1,469 11,080 13.3
Sacramento County 790 5,920 13.3 978 5,920 16.5 758 5,920 12.8
San Bernardino County 601 11,890 5.1 770 11,890 6.5 589 11,890 5.0
San Diego County 3,395 14,500 23.4 3,877 14,500 26.7 3,083 14,500 21.3
San Francisco County 7,912 10,840 73.0 8,886 10,840 82.0 6,908 10,840 63.7
District of Columbia 5,045 12,950 39.0 5,941 12,950 45.9 4,929 12,950   38.1
Florida
Broward County 2,786 20,470 13.6 3,754 20,470 18.3 4,540 20,470 22.2
Duval County 375 8,970 4.2 517 8,970 5.8 504 8,970 5.6
Hillsborough County 1,118 12,910 8.7 1,459 12,910 11.3 1,187 12,910 9.2
Miami-Dade County 3,824 21,760 17.6 6,607 21,760 30.4 7,290 21,760 33.5
Orange County 1,870 15,310 12.2 2,827 15,310 18.5 2,764 15,310 18.1
Palm Beach County 576 9,170 6.3 892 9,170 9.7 1,525 9,170 16.6
Pinellas County 781 9,530 8.2 1,108 9,530 11.6 897 9,530 9.4
Georgia
Cobb County 383 3,070 12.5 571 3,070 18.6 496 3,070 16.2
DeKalb County 1,188 6,290 18.9 1,573 6,290 25.0 1,339 6,290 21.3
Fulton County 2,574 13,120 19.6 3,308 13,120 25.2 2,798 13,120 21.3
Gwinnett County 455 3,240 14.0 698 3,240 21.5 608 3,240 18.8
Illinois
Cook County 11,471 39,060 29.4 13,682 39,060 35.0 10,452 39,060 26.8
Indiana
Marion County 853 9,150 9.3 1,149 9,150 12.6 906 9,150 9.9
Louisiana
East Baton Rouge Parish 442 1,810 24.4 509 1,810 28.1 394 1,810 21.8
Orleans Parish 1,358 4,590 29.6 1,635 4,590 35.6 1,092 4,590 23.8
Maryland
Baltimore City 651 6,330 10.3 918 6,330 14.5 720 6,330 11.4
Montgomery County 797 5,770 13.8 961 5,770 16.7 728 5,770 12.6
Prince George’s County 645 4,040 16.0 835 4,040 20.7 637 4,040 15.8
Massachusetts
Suffolk County 2,488 6,520 38.2 3,136 6,520 48.1 2,664 6,520 40.9
Michigan
Wayne County 1,035 9,270 11.2 1,289 9,270 13.9 956 9,270 10.3
Nevada
Clark County 1,277 11,670 10.9 1,888 11,670 16.2 1,482 11,670 12.7
New Jersey
Essex County 591 4,090 14.4 708 4,090 17.3 528 4,090 12.9
Hudson County 858 4,650 18.5 1,070 4,650 23.0 847 4,650 18.2
New York
Bronx County 2,030 5,570 36.4 2,302 5,570 41.3 1,546 5,570 27.8
Kings County 6,278 15,650 40.1 7,503 15,650 47.9 5,705 15,650 36.5
New York County 12,276 15,540 79.0 14,172 15,540 91.2 11,199 15,540 72.1
Queens County 3,336 9,230 36.1 3,965 9,230 43.0 3,010 9,230 32.6
North Carolina
Mecklenburg County 957 8,450 11.3 1,372 8,450 16.2 1,219 8,450 14.4
Ohio
Cuyahoga County 819 7,520 10.9 988 7,520 13.1 738 7,520 9.8
Franklin County 1,622 11,620 14.0 2,060 11,620 17.7 1,794 11,620 15.4
Hamilton County 441 7,720 5.7 559 7,720 7.2 462 7,720 6.0
Pennsylvania
Philadelphia County 3,237 9,840 32.9 3,719 9,840 37.8 2,762 9,840 28.1
Puerto Rico
San Juan Municipio d 2,190 n/a d 2,190 n/a d 2,190 n/a
Tennessee
Shelby County 466 6,450 7.2 645 6,450 10.0 598 6,450 9.3
Texas
Bexar County 1,114 11,920 9.3 1,491 11,920 12.5 1,231 11,920 10.3
Dallas County 3,251 28,670 11.3 4,221 28,670 14.7 3,852 28,670 13.4
Harris County 3,873 40,670 9.5 4,957 40,670 12.2 4,531 40,670 11.1
Tarrant County 1,179 11,340 10.4 1,497 11,340 13.2 1,182 11,340 10.4
Travis County 3,414 11,590 29.5 4,608 11,590 39.8 3,931 11,590 33.9
Washington
King County 6,112 17,890 34.2 7,373 17,890 41.2 6,515 17,890 36.4

Abbreviations: PrEP, preexposure propphylaxis; n/a, not available.

aEstimated using data from IQVIA pharmacy database reported through June 2020 based on an algorithm that included FDA approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
bEstimated using 2018 data from National HIV Surveilance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2018, 2019 and 2020 PrEP coverage data.
cPrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
dData value <40 was not reported due to unreliability.